Roflumilast

Roflumilast

Clinical data
Trade names	Daxas, Daliresp, Zoryve, others
AHFS/Drugs.com	Monograph
MedlinePlus	a611034
License data	EU EMA: by INN US DailyMed: Roflumilast US FDA: Roflumilast
Pregnancy category	AU: B3
Routes of administration	By mouth, topical
ATC code	R03DX07 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only UK: POM (Prescription only) US: ℞-only EU: Rx-only
Pharmacokinetic data
Bioavailability	79%
Protein binding	99%
Metabolism	Hepatic via CYP1A2 & CYP3A4
Elimination half-life	17 hours (30 hours [active metabolite])
Excretion	Urine (70%)
Identifiers
IUPAC name 3-(Cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide
CAS Number	162401-32-3 N
PubChem CID	449193
IUPHAR/BPS	6962
DrugBank	DB01656 Y
ChemSpider	395793 N
UNII	0P6C6ZOP5U
KEGG	D05744
ChEBI	CHEBI:47657 N
ChEMBL	ChEMBL193240 N
PDB ligand	ROF (PDBe, RCSB PDB)
CompTox Dashboard (EPA)	DTXSID8044123
ECHA InfoCard	100.210.960
Chemical and physical data
Formula	C17H14Cl2F2N2O3
Molar mass	403.21 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F
InChI InChI=1S/C17H14Cl2F2N2O3/c18-11-6-22-7-12(19)15(11)23-16(24)10-3-4-13(26-17(20)21)14(5-10)25-8-9-1-2-9/h3-7,9,17H,1-2,8H2,(H,22,23,24) N Key:MNDBXUUTURYVHR-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Roflumilast, sold under the trade name Daxas among others, is a drug that acts as a selective, long-acting inhibitor of the enzyme phosphodiesterase-4 (PDE-4). It has anti-inflammatory effects and is used as an orally administered drug for the treatment of inflammatory conditions of the lungs such as chronic obstructive pulmonary disease (COPD).

In June 2010, it was approved in the European Union for severe COPD associated with chronic bronchitis. In February 2011, it gained FDA approval in the United States for reducing COPD exacerbations. It is available as a generic medication.

Medical uses

Roflumilast is indicated for the treatment of severe chronic obstructive pulmonary disease (COPD) and for the treatment of plaque psoriasis.

It is used in the prevention of exacerbations (lung attacks) in severe chronic obstructive pulmonary disease (COPD).

Adverse effects

Common (1–10% incidence) adverse effects include:

• Diarrhea
• Weight loss
• Nausea
• Headache
• Insomnia
• Decreased appetite
• Abdominal pain
• Rhinitis
• Sinusitis
• Urinary tract infection
• Depression

External links

• "Roflumilast". Drug Information Portal. U.S. National Library of Medicine.